Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pivotal study of olverembatinib in chronic-phase chronic myeloid leukemia with T315I mutation
CTR20190274Phase 2Active
- Sponsor
- 广州顺健生物医药科技有限公司
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib in chronic myelogenous leukemia (CML), sponsored by 广州顺健生物医药科技有限公司. Started Apr 2019; status: active.
02
Drugs
olverembatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20190274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190274.